ORINF (ORINF) Stock Price & Analysis
ORINF (ORINF) rose 0.00% to USD 82.75 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.
ORINF last closed at USD 82.75; the session ranged USD 82.75–82.75 on volume of 100 shares. Market capitalization is $11.66B, with a 52-week range of USD 48.65–82.75 (PNK). Source: Nexqual, June 9, 2026 at 23:49 UTC.
Key Statistics (as of June 9, 2026 at 23:49 UTC)
| Price | USD 82.75 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 82.75 |
| Open | USD 82.75 |
| Day Range | USD 82.75 – 82.75 |
| 52-Week Range | USD 48.65 – 82.75 |
| Volume | 100 shares |
| Market Cap | $11.66B |
| Exchange | PNK |
Technical Analysis (ORINF)
Nexqual's technical model rates ORINF "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 82.52) |
| MACD | 0.1 (positive) |
Analyst Ratings (ORINF)
Wall Street analysts rate ORINF "None", per Nexqual as of June 9, 2026 at 23:49 UTC.
| Consensus Rating | None |
|---|
Earnings (ORINF)
| Next Earnings Date | 2026-07-17 |
|---|---|
| Revenue Estimate | $507.14M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financials & Fundamentals (ORINF)
| Total Revenue | $1.95B |
|---|---|
| Revenue Growth (YoY) | +17.80% |
| Gross Margin | +64.80% |
| Operating Margin | +27.46% |
| Profit Margin | +27.11% |
| ROE | +48.37% |
| Debt / Equity | 29.43 |
| Current Ratio | 1.77 |
| Total Cash | $199.30M |
| Total Debt | $330.30M |
| Free Cash Flow | $328.26M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financial Health Score (ORINF)
Nexqual rates ORINF's overall financial health "Strong" across five dimensions, as of June 9, 2026 at 23:49 UTC.
| Growth | Strong — Revenue +23% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 65%, operating 27% |
| Balance Sheet | Strong — $199M cash vs $330M debt |
| Cash Flow | Strong — FCF $328M, 17% margin |
| Efficiency | Strong — ROE 48%, ROA 22.1% |
Ownership (ORINF)
| Insider Ownership | +2.64% |
|---|---|
| Institutional Ownership | +44.50% |
| Shares Outstanding | 109.34M |
| Float | 123.11M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Leadership (ORINF)
ORINF is led by Liisa Hurme (age 58), President, CEO & Chairman of Executive Management Board, per Nexqual as of June 9, 2026 at 23:49 UTC.
| President, CEO & Chairman of Executive Management Board | Liisa Hurme (age 58) |
|---|---|
| CFO & Member of Group Executive Management Board | Rene Lindell M.Sc. (age 49) |
| Executive Vice President of Innovative Medicines & Member of Management Board | Berkeley Vincent (age 48) |
Major Backers & Investors (ORINF)
Notable institutional backers of ORINF include DFA INVESTMENT TRUST CO-The Continental Small Company Series, Fidelity, Charles Schwab, according to Nexqual as of June 9, 2026 at 23:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Continental Small Company Series | 1% |
| Fidelity | 0.37% |
| Charles Schwab | 0.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.75% |
| BlackRock | 1.07% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORINY | Orion Corporation OY | USD 40.63 | ▲ 6.96% |
| DSRLF | DIASORIN SPA | USD 84.1 | ▲ 0% |
| OPHLF | Ono Pharmaceutical Co., Ltd. | USD 14.55 | ▲ 0% |
| HKMPY | Hikma Pharmaceuticals plc. | USD 39.08 | ▼ 0.48% |
| MKGAF | Merck KGaA | USD 159.71 | ▼ 2.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.